Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Weekly Wrap 21 April

Grady Wulff
April 21, 2023

Morning Bell 21 April

Sophia Mavridis
April 21, 2023

Morning Bell 20 April

Grady Wulff
April 20, 2023

Morning Bell 19 April

Grady Wulff
April 19, 2023

Morning Bell 18 April

Sophia Mavridis
April 18, 2023

Morning Bell 17 April

Grady Wulff
April 17, 2023

Weekly Wrap 14 April

Grady Wulff
April 14, 2023

Morning Bell 14 April

Sophia Mavridis
April 14, 2023

Morning Bell 13 April

Grady Wulff
April 13, 2023

Morning Bell 12 April

Grady Wulff
April 12, 2023

Morning Bell 11 April

Sophia Mavridis
April 11, 2023

Morning Bell 6 April

Sophia Mavridis
April 6, 2023